The present invention generally relates to various methods for promoting ovulation, parturition and lactation in female mammals. These bene?ts are obtained by administering to the mammals a composition containing a D2 receptor antagonist that does not substantially cross the blood brain barrier. In one embodiment, the D2 receptor antagonist is domperidone. The domperidone can be administered to the mammal either orally or subcutaneously and can be used to treat, for instance, anestrous mammals, mammals that have problems bearing offspring and mammals suffering from agalactia. Unexpectedly, it has also been discovered that the D2 receptor antagonist may also stimulate feed intake, causing the mammal to eat more and gain Weight faster.
The present invention generally relates to a method for promoting ovulation, parturition and lactation in female mammals. More particularly, the present invention is directed to a method of administering a dopamine D2
receptor antagonist, such as domperidone, to a female mam mal for altering hormonal levels in the animal in order to promote ovulation, parturition or lactation.
BACKGROUND OF THE INVENTION
Breeders of various animals, such as horses and other livestock, face many problems in getting the animals to breed properly. For instance, some female mammals fail to ovulate and fall into heat in regular intervals. Mammals that exhibit a prolonged period of inactivity betWeen tWo periods of heat are described as being anestrous. Anestrous female mammals Will not accept the male and are incapable of conceiving offspring.
Another problem breeders experience is the inability of some mammals to prepare for and give birth after the mammals have become pregnant and the fetus is ready to be born. In preparation for and during the act of giving birth, a process knoWn as parturition, the pregnant mammal should experience cervical relaxation, sWelling of the vulva, and relaxation of ligaments around the pelvis. Without these events occurring, the mammal is not capable of giving natural, unassisted birth. Further, should these events not occur, the health of the mother and of the unborn offspring are at grave risk.
Another problem commonly experienced by breeders is the inability of mammals to produce and secrete milk after giving birth. The condition of failing to lactate properly after child birth is referred to as agalactia, and is especially prevalent in mares and other livestock. Should the mammal not lactate properly, the offspring must then be bottle fed Which is time consuming, labor intensive, and signi?cantly adds to the cost of raising the livestock. Each of the problems mentioned above can be caused to a great extent by hormonal imbalance or by hormonal irregularities. Hormones released in the body are primarily responsible for initiating ovulation, parturition, and lactation in mammals. Thus, if hormones are not released in the body at particular critical times, the above described problems can be experienced.
For instance, hormones can be prevented from being released in the body by various chemical agents. One such knoWn chemical agent is dopamine. Dopamine is a decar boxylated form of dopa and is found and produced in the adrenal glands of mammals. Dopamine is believed to be produced by the body When it is necessary to suppress hormone secretion. Dopamine suppresses hormone release by binding to and tying up receptors on the anterior pituitary, an endocrine gland located at the base of the brain not far from the hypothalamus. By binding to the anterior pituitary, the gland is prevented from receiving a stimulus hormone that causes it to release other hormones such as those necessary for ovulation, parturition, and lactation.
Although dopamine is necessary during particular periods The present invention recogniZes and addresses the fore going disadvantages, and others of prior art constructions and methods.
Accordingly, it is an object of the present invention to provide a process for promoting ovulation and for treating anestrous mammals.
Another object of the present invention is to provide a method for promoting parturition in a pregnant mammal that is at the end of the pregnancy cycle.
It is another object of the present invention to provide a process for promoting lactation and for treating agalactia in mammals that have just given birth. Still another object of the present invention is to provide a process for controlling hormonal release in the body.
Another object of the present invention is to provide a method for altering hormone levels in the body of a mammal by administering to the mammal a dopamine antagonist.
It is another object of the present invention to provide a process for treating a mammal that has excess levels of dopamine and other similar acting agents Within its body.
These and other objects of the present invention are achieved by providing a method for promoting follicular groWth and ovulation, for preparing a mammal for parturition, and for promoting lactation by administering to a female mammal a composition. The composition contains a dopamine D2 receptor antagonist. For instance, in one embodiment, the composition can contain domperidone.
The present inventor has used domperidone in the past for treating animals suffering from fescue toxicosis. For instance, the present inventor's prior Work is disclosed in US. Pat. No. 5 , 372, 818 When attempting to promote parturition, udder development, and lactation, on the other hand, domperidone can be administered orally to a mammal at a dosage of from about 0.2 mg to about 3.3 mg and particularly at about 1.1 mg per kilogram Weight of the mammal. When administered subcutaneously, the dosage of domperidone can be from about 0.08 mg to about 1.32 mg and particularly at about 0.44 mg per kilogram Weight of the mammal.
All of the above dosage levels according to the present invention can be given daily. Although unknoWn, it is believed that the treatments cause hormonal levels in the mammal to change for promoting either ovulation, parturi tion or lactation. Unexpectedly, it has also been discovered that a dopamine D2 receptor antagonist such as domperidone may also cause an increase in feed intake in the mammal resulting in Weight increases.
Other objects, features and aspects of the present inven tion are discussed in greater detail beloW.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodi ments only, and is not intended as limiting the broader aspects of the present invention, Which broader aspects are embodied in the exemplary construction. The present invention is generally directed to various processes and methods for promoting and stimulating folli cular groWth and ovulation, for preparing a mammal for parturition, and for promoting and stimulating udder devel opment and lactation. The process of the present invention can be used to treat anestrous mammals, agalactic mammals, and more generally any mammal experiencing problems during the reproductive cycle. The process of the present invention can also be used to manipulate and control ovu lation and lactation. For instance, in mammals that only ovulate seasonally, the present invention can be used to promote ovulation at times When ovulation Would not nor mally occur.
In general, the objects and advantages of the present invention are achieved by administering to a female mam mal a composition containing a dopamine D2 receptor antagonist. A D2 receptor antagonist should be chosen but does not substantially cross the blood brain barrier in order to ensure that the mammal does not suffer any adverse behavioral or neurological side effects. For instance, in a preferred embodiment, the dopamine D2 receptor antagonist is domperidone.
Although unknoWn, it is believed that domperidone ties up receptor cells in the anterior pituitary and other places in the body preventing various chemical agents, such as dopamine, from binding to the receptor cells and altering the release of hormones throughout the body. By altering the effects of dopamine and other similar agents, domperidone alloWs the anterior pituitary and other glands of the body to secrete hormones necessary for ovulation, parturition, and lactation as Will be described in greater detail hereinafter.
As discussed above, one embodiment of the present invention is directed to a process for stimulating and pro moting follicular groWth and ovulation. The process can be used to treat anestrous mammals, to cause a mammal to ovulate out of season, or to otherWise control When ovula tion occurs.
The process of the present invention can be used to treat any mammal, but is particularly applicable to livestock. For instance, many problems have been experienced in attempt ing to get horses to breed. Further, mares only ovulate and fall into heat during particular times of the year. The process of the present invention cannot only be used to treat horses that experience problems ovulating but can also be used to breed horses during times of the year When it Was not before possible.
According to the present invention, follicular groWth and ovulation is promoted by administering to a mammal a dopamine D2 receptor antagonist. In one preferred embodiment, the dopamine D2 receptor antagonist is dom peridone. The D2 receptor antagonist can be taken orally by the mammal or can be injected subcutaneously.
In one embodiment, When using domperidone, it has been found that ovulation is promoted When the domperidone is taken orally by a mammal in an amount from about 0. Besides promoting ovulation, the present invention is also directed to a process for preparing a mammal for parturition.
This process is for treating mammals and particularly live stock that have problems giving birth once pregnant. US 6, 224, 895 B1 5 Parturition is stimulated in a mammal according to the present invention by administering to the mammal a com position containing a dopamine D2 receptor antagonist. For instance, in one embodiment, the composition can contain domperidone. Once administered to the mammal, it is believed that the composition neutraliZes the effects of dopamine and other similar chemical agents from altering the release of hormones that prepare a mammal for giving birth. Thus, the composition of the present invention alloWs the body to secrete hormones that may affect cervical dilation and general broodiness.
By administering the composition to pregnant mammals, the mammal is more likely to give birth on time. The composition also promotes natural births and prevents against having to deliver the offspring by C-sections. The treatment not only protects the unborn offspring during delivery but also protects the pregnant mother from being harmed during birth.
In order to promote normal parturition, in one embodiment, a pregnant mammal can be orally fed domp eridone at a concentration of from about 0.2 mg/kg of body Weight to about 3.3 mg/kg. In one preferred embodiment, the oral dosage can be about 1.1 mg/kg.
When injected subcutaneously into the mammal, domp eridone has been found to produce effective results at concentrations of from about 0.08 mg/kg to about 1.32 mg/kg, With best results being obtained at about 0.44 mg/kg.
Amounts greater than 1.32 mg/kg can be administered to the animal Without any adverse side effects. Additional bene?ts, hoWever, have not been observed at higher dosage levels.
Whether administered orally or subcutaneously, treat ments of the D2 receptor antagonist administered to the mammal can begin at any time during the pregnancy. For larger livestock such as cattle and horses, the treatment should begin about ?fteen to tWenty days prior to the eXpected birth date.
Afurther embodiment of the present invention is directed to a process for promoting udder development and lactation in female mammals. The process can be used to prevent or treat agalactia or any other ailments regarding the loW level or non-production of milk. For instance, lactation problems have been particularly observed in mares that have recently given birth. After giving birth, many mares either fail to produce milk or do not produce enough milk to adequately nurture the foal. When this occurs, the foal must be bottle fed or fed in some other manner Which signi?cantly adds to the eXpense of raising the livestock.
The process of the present invention can be used in these circumstances to stimulate or increase milk production in non-milking mares and other mammals. Further, the process can be used simply to increase milk production Without any adverse effects. For instance, the process of the present invention can also be used to increase the quantity of milk obtained from coWs for human consumption.
Lactation is stimulated and promoted according to the present invention by administering to mammals a composi tion containing a dopamine D2 receptor antagonist. For instance, the composition can contain domperidone in an amount suf?cient to stimulate milk production.
In one embodiment, milk production Was stimulated in horses by orally administering to the horses domperidone in Besides promoting ovulation, preparing a mammal for parturition, and stimulating lactation, it has also been uneX pectedly discovered that the composition of the present invention can cause a mammal to increase its feed intake and thus gain Weight faster. This process is particularly bene? cial in raising livestock for human consumption.
In order to increase feed intake according to the present invention, a dopamine D2 receptor antagonist, such as domperidone, is administered to a mammal. The treatment can be given to the mammal orally or subcutaneously. If domperidone is used and administered orally, the domperi done should be fed to the mammal at a concentration of from about 0.2 mg/kg of body Weight to about 3.3 mg/kg of body Weight and particularly at about 1.1 mg/kg. If domperidone is injected into the mammal, the dosage should be from about 0.08 mg/kg to about 1.32 mg/kg.
At the present time, it is unknoWn Why domperidone causes increases in feed intake. It is believed, hoWever, that domperidone may stimulate feed intake by increasing levels of the hormone prolactin in the body of the mammal. It may also be possible that domperidone causes levels of hormones to be altered that ?rm up the gut of the mammal. If the muscles of the gut Were to be stimulated, then food passage may increase in the gut alloWing the animal to eat more.
In general, in delivering an effective dosage of a dopam ine D2 receptor antagonist to a mammal according to the present invention, various vehicles may be used. For instance, When taken orally, the D2 receptor antagonist may be combined With a feed or feed supplement material as the carrier. If injected, the drug may be miXed With any suitable carrier. Additionally, the D2 receptor antagonist, such as domperidone, may be added to salt blocks or mineral blocks during casting or miXed directly into feed. Further, various other administration techniques Well knoWn in the art may be employed. It is to be understood that the present invention is not to be limited to any particular vehicle.
It also should be appreciated that although the above description and folloWing eXamples relate primarily to live stock such as horses and cattle, it is believed that the drug Will Work as described With any mammal. For instance, although untested at the present time, it is believed that a dopamine D2 receptor antagonist that does not substantially cross the blood brain barrier such as domperidone may be administered to humans for promoting ovulation, facilitating childbirth, or stimulating lactation.
The present invention may be better understood With reference to the folloWing examples. 
